Back
About the Global Fund
Results Report 2021
-
Programs supported by the Global Fund partnership had saved 44 million lives as of the end of 2020. But over the last year, the impact of the COVID-19 pandemic has been devastating.
- Read the online report
People & Structures
Back
Funding Model
Investments & Results
Explore contributions, investments and results in our fight against AIDS, tuberculosis and malaria around the world.
Back
News
-
11 November 2021
United States to Host Next Global Fund Replenishment Conference -
11 November 2021
Lifeline Support from UNDP and the Global Fund Keeps Afghanistan’s Health Facilities Open -
10 November 2021
Global Fund Board Approves New Strategy Placing People and Communities at Center to Lead Fight Against HIV, TB, Malaria, to Build Systems for Health, Equity and Strengthen Pandemic Preparedness
Updates
Stories
Back
Featured Publication
Documents by type
GF/B09/DP18
Approved by the Board on: 19 November 2004
Quality Assurance of Single- and Limited-Source Pharmaceutical Products
The Board replaces the phrase "Option (c) is applicable only until December 31, 2004" in the Board decision on quality assurance (compliance with quality standards) from the Third Board Meeting (GF/B4/2, p. 23) with "Option (c) is applicable only until December 31, 2005
The Board invites the World Health Organization to work with the Secretariat to assess the impact of the expiry of the transition period established in Option (c) and to develop options on the quality assurance of single- and limited-source products, and to report back to the PMPC in time for the development of recommendations for the Tenth Board Meeting.
Budgetary Implications
The additional cost of implementing this decision is estimated as US$60,000.
The Global Fund uses cookies for anonymized statistics on website use and content performance to help us improve and adapt the website. To consent to the use of cookies, please click “Accept”. To learn more about your rights and options, please read our Privacy Statement.